Huntington’s gene therapy research has reached a turning point, expert says
Despite unanticipated regulatory hurdles following promising clinical results with a novel investigational treatment for Huntington’s Disease, the significance of the…
All articles by Irena Maragkou
Irena Maragkou
Irena Maragkou is a Healthcare Researcher for Clinical Trials Arena and Pharmaceutical Technology based in London, UK. Irena previously worked in consulting at Deloitte’s Strategy, M&A and Analytics Department, focusing on projects in the Pharmaceutical and Healthcare Sector. She holds an MSci degree in Neuroscience from UCL.
-
-
Navigating the FDA’s import operations for pharmaceuticals and biologics
In August 2025, the US Food and Drug Administration’s (FDA) launched the nationalised entry review (NER) programme focused on centralising…
-
Advancing rare disease trials by overcoming patient recruitment challenges
Next month, clinical development and clinical operations professionals will gather and discuss the current challenges in running clinical trials for…
-
IRA holds the scope to shape pharma’s research strategy, say experts
Pharma companies will need to rethink business and research and development (R&D) strategies to mitigate against the global impact that…
-
European agencies catch up with speedier regulatory pathways for CGTs in the US
Although the regulatory landscape for advanced therapy medicinal products (ATMPs) is rapidly evolving, varying regulatory requirements across different regions are…
-
Investment surges, hurdles and emerging innovations in neuroscience
Innovation in neuropsychiatry has been dormant for nearly forty years, said Kabir Nath, CEO, Compass Pathways in a panel discussion…
-
CPHI Europe: how AI can drive growth in the nutraceutical space
“Consumer demands drive flexible and optimised manufacturing processes and also infrastructure,”said Catarina Abreu, Head of Nutraceuticals at PIPA AI. At…
-
CPHI Europe: strategies to navigate nitrosamines risk evaluation
Drug impurities such as nitrosamines can often contaminate drugs leading to recalls and regulatory actions given their carcinogenic nature. These…
-
Cell and gene therapy approvals drive paradigm change in manufacturing
Innovative cell and gene therapies (CGTs) have significantly disrupted the treatment landscape for several genetic diseases. In recent years, the…
-
CPHI Europe: Targeting supply chain bottlenecks key for cell and gene therapies
Cell therapies stand at the frontier of medicine and hold the potential to potentially cure diseases, said Angela Vollstedt, global…